期刊
DRUG DESIGN DEVELOPMENT AND THERAPY
卷 16, 期 -, 页码 685-715出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S354841
关键词
SARS-CoV-2; drug repurposing; clinical trials; molnupiravir; paxlovid
资金
- research center at Almaarefa University
This article provides a comprehensive review of drug repurposing for COVID-19 and the latest available oral anti-SARS-CoV-2 medications, discussing clinical trials, combination therapies, novel methods, and future prospects.
The rising outbreak of SARS-CoV-2 continues to unfold all over the world. The development of novel effective antiviral drugs to fight against SARS-CoV-2 is a time cost. As a result, some specific FDA-approved drugs have already been repurposed and authorized for COVID-19 treatment. The repurposed drugs used were either antiviral or non-antiviral drugs. Accordingly, the present review thoroughly focuses on the repurposing efficacy of these drugs including clinical trials experienced, the combination therapies used, the novel methods followed for treatment, and their future perspective. Therefore, drug repurposing was regarded as an effective avenue for COVID-19 treatment. Recently, molnupiravir is a prodrug antiviral medication that was approved in the United Kingdom in November 2021 for the treatment of COVID-19. On the other hand, PF-07321332 is an oral antiviral drug developed by Pfizer. For the treatment of COVID-19, the PF-07321332/ritonavir combination medication is used in Phase III studies and was marketed as Paxlovid. Herein, we represented the almost history of combating COVID-19 from repurposing to the recently available oral antiSARS-CoV-2 candidates, as a new hope to end the current pandemic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据